STADA Arzneimittel AG: Voting results of the bondholders’ meeting concerning the STADA-Bond 2015/2022

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond

18.09.2018 / 15:07

The issuer is solely responsible for the content of this announcement.

Bad Vilbel, 18 September 2018 – STADA Arzneimittel Aktiengesellschaft (“STADA” or the “Issuer“) today informed about the voting results of the meeting on 18 September 2018 (the “Bondholders’ Meeting“) of the bondholders (the “Bondholders“) of the EUR 300,000,000 1.750% bonds, due 2022, ISIN: XS1213831362, Common Code: 121383136, WKN: A14KJP (the “Bond“).

The purpose of today’s meeting was to set the basis for the Bondholders to participate in certain security interests. It was planned to pass a resolution on the instruction of the joint representative of the Bondholders to accede to the intercreditor agreement and on certain technical changes to the Bond’s terms and conditions.

Since the Bondholders’ Meeting did not reach the quorum required for the resolutions on these agenda items, no resolutions could be passed.

Further details of the Bondholders’ Meeting are available on the STADA website at

About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail:
Or visit us on the Internet at

Additional information for capital market participants:
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail:
Or visit us on the Internet at

18.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: STADA Arzneimittel AG
Stadastra├če 2-18
61118 Bad Vilbel
Phone: +49 (0)6101 603-4689
Fax: +49 (0)6101 603- 215
ISIN: DE0007251803
WKN: 725180
Listed: Regulated Market in Dusseldorf, Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of News DGAP News Service

show this